Dichloroacetate (DCA) and Fibromyalgia: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Dichloroacetate (DCA) and Fibromyalgia: Latest Research 2026

This page summarizes the current state of scientific research on Dichloroacetate (DCA) in the context of Fibromyalgia as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your rheumatologist for personalized guidance.

Compound Overview

Dichloroacetate (DCA) (Metabolic / Pyruvate Dehydrogenase Kinase Inhibitor) — Not FDA-approved; investigational for cancer and metabolic disorders

Mechanism of action: Inhibits PDK; shifts glucose metabolism from glycolysis to OXPHOS; reactivates mitochondria in cancer cells; pro-apoptotic

Current evidence level: Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity

2026 Research Landscape

Direct research on Dichloroacetate (DCA) specifically for Fibromyalgia remains limited as of 2026, though the mechanistic connections continue to be explored in laboratory settings.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Dichloroacetate (DCA) affects the biological pathways involved in Fibromyalgia progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Screening studies: Preclinical models are still being used to establish whether clinical investigation is warranted

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Dichloroacetate (DCA)[tiab]) AND (Fibromyalgia[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Dichloroacetate (DCA) keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Dichloroacetate (DCA) + Fibromyalgia research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in Fibromyalgia patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Dichloroacetate (DCA) for Fibromyalgia?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Dichloroacetate (DCA) Fibromyalgia' filtered to the last 2 years. The current evidence level is: Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity.

Are there any 2025-2026 clinical trials for Dichloroacetate (DCA) in Fibromyalgia?

Check ClinicalTrials.gov with 'Dichloroacetate (DCA)' as intervention and 'Fibromyalgia' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your rheumatologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Dichloroacetate (DCA) in Fibromyalgia changed recently?

The field evolves rapidly. The current evidence classification is: Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.